GSK

Britain signs supply deal for 60 mln doses of Sanofi/GSK COVID-19 vaccine

Credit: REUTERS/CHARLES PLATIAU

Britain has signed a supply deal for up to 60 million doses of a possible COVID-19 vaccine being developed by Sanofi and GlaxoSmithKline, it said on Wednesday, its fourth such arrangement.

Adds details

LONDON/PARIS, July 29 (Reuters) - Britain has signed a supply deal for up to 60 million doses of a possible COVID-19 vaccine being developed by Sanofi SASY.PA and GlaxoSmithKline GSK.L, it said on Wednesday, its fourth such arrangement.

No vaccine has yet been approved to treat or prevent COVID-19, the respiratory disease caused by the coronavirus that has killed more than 659,000 people and unleashed economic havoc worldwide.

Financial terms of the agreement were not disclosed. Sanofi and GSK, which had first teamed up in April, confirmed in a statement that regulatory approval for their vaccine could be won by the first half of 2021 if clinical data was positive.

Britain has moved early in striking vaccine supply deals, and ministers have stressed the importance of securing supplies of a range of candidates.

"The fact remains that there are no guarantees," said business minister Alok Sharma.

"In the meantime, it is important that we secure early access to a diverse range of promising vaccine candidates, like GSK and Sanofi, to increase our chances of finding one that works."

Last week Britain struck deals for 30 million doses of the experimental BioNTech/Pfizer vaccine, and a deal in principle for 60 million doses of the Valneva vaccine.

That followed a previously announced pact with AstraZeneca AZN.L for production of 100 million doses of its potential vaccine, being developed in partnership with Oxford university.

With no working vaccine against COVID-19 yet developed, Britain now has 250 million doses potentially available.

(Reporting by Alistair Smout in London and Matthias Blamont in Paris; Editing by Clarence Fernandez)

((alistair.smout@thomsonreuters.com; +44 207 542 7064; Reuters Messaging: alistair.smout.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GSK AZN

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More